Anaplastic Large-Cell Lymphoma

This is a type of non-Hodgkin lymphoma. It's called 'anaplastic' because the cancer cells look very abnormal under a microscope. Doctors often call it 'Large-Cell' because the cells are big. It's a serious cancer that affects the immune system. It's often mistaken for other cancers, so it needs careful diagnosis.

Condition

What people with Anaplastic Large-Cell Lymphoma report

Every report comes from a Lived member, sent anonymously.

Have you tried Adcetris (Brentuximab Vedotin) for Anaplastic Large-Cell Lymphoma?

NameHow it went

About Anaplastic Large-Cell Lymphoma

What It Is

Anaplastic large-cell lymphoma (ALCL) is a rare cancer of the immune system. It is a type of non-Hodgkin lymphoma that starts in T cells, a kind of white blood cell, and it accounts for about 2 out of every 100 lymphomas. Under the microscope the cancer cells are large and unusual-looking, and they carry a protein on their surface called CD30. That marker helps confirm the diagnosis, and some treatments are designed to target it. ALCL is not one disease with one outlook. Systemic ALCL can involve lymph nodes and other parts of the body, including the skin, and it often causes swollen lymph nodes along with fever, drenching night sweats, weight loss or tiredness. Doctors divide systemic ALCL by whether the cancer cells make an abnormal protein called anaplastic lymphoma kinase (ALK). ALK-positive ALCL mainly affects children, teenagers and young adults and usually responds well to treatment. ALK-negative ALCL is more common in older adults and is more likely to come back after treatment. Two other forms behave quite differently. Primary cutaneous ALCL stays in the skin, usually as one or a few firm red bumps or nodules, and tends to grow slowly. Breast implant-associated ALCL develops in the fluid or scar tissue that forms around a breast implant. Despite its location, it is a lymphoma, not breast cancer.

Causes & Risk Factors

For most people with systemic or skin-limited ALCL, no cause can be identified, and nothing they did is known to have brought it on. In ALK-positive ALCL, an exchange of genetic material between two chromosomes (most often chromosomes 2 and 5) inside the lymphoma cells switches on the ALK protein, which pushes the cells to keep growing and surviving. This change arises in the lymphoma cells themselves; it explains how the cancer grows but not why it started. The clearest known risk factor applies to the breast implant form. Breast implant-associated ALCL almost always occurs with implants that have a textured surface, and it typically appears years after the implant was placed. The risk is low, estimated at roughly 1 in 12,000, though that estimate may rise as people are followed for longer. Whether an implant is filled with saline or silicone does not appear to affect the risk. The FDA does not recommend removing implants in people who have no symptoms.

How It's Diagnosed

Diagnosis requires a biopsy: a sample of the affected lymph node, skin or other tissue that a pathologist examines under a microscope. Special stains show whether the cells carry CD30 and whether they make ALK. The ALK result matters because it separates the two main kinds of systemic ALCL and shapes the expected outlook. ALCL can resemble other cancers and some noncancerous conditions, so these added tests are what make the diagnosis certain. Once ALCL is confirmed, staging tests show how far it has spread. These usually include blood tests and imaging such as a CT scan or a PET scan (an imaging test that uses a small injected tracer to show where cancer is active), and sometimes a bone marrow biopsy. For a lymphoma found in the skin, a key question is whether it is truly limited to the skin, because skin involvement from systemic ALCL is treated very differently from primary cutaneous ALCL. For a possible breast implant-associated ALCL, evaluation involves imaging and testing of the fluid or tissue around the implant for CD30 and ALK, and the diagnosis can change what kind of surgery is needed.

Treatment Options

Treatment depends on the form of ALCL, how far it has spread and the person's age. For adults with newly diagnosed systemic ALCL, the standard approach combines chemotherapy with brentuximab vedotin (Adcetris). Brentuximab is an antibody linked to a cell-killing drug: it attaches to CD30 on the lymphoma cells and carries the drug into them. It is given by IV infusion together with three chemotherapy drugs (cyclophosphamide, doxorubicin and prednisone). In a large international trial, this combination helped more people live longer than the older standard chemotherapy combination, which used vincristine in place of brentuximab. Its most important trade-off is nerve damage in the hands and feet, felt as numbness, tingling or pain, which builds up with each dose; the care team checks for it so doses can be adjusted before it becomes severe. Some adults whose lymphoma responds well, particularly those with ALK-negative ALCL, are offered high-dose chemotherapy followed by a return of their own previously collected stem cells (an autologous stem cell transplant) to make the remission more durable. The evidence for this comes from observational studies rather than randomized trials, so it is a case-by-case decision. If systemic ALCL comes back or does not respond, options include brentuximab vedotin, other targeted medicines, clinical trials and stem cell transplantation, sometimes using cells from a donor. For ALK-positive disease, ALK inhibitors are an important option. Crizotinib (Xalkori), a pill that blocks the ALK protein, is FDA-approved for relapsed or hard-to-treat ALK-positive ALCL in children 1 year and older and young adults. Children and teenagers with ALCL, nearly all of whom have ALK-positive disease, respond well to combination chemotherapy at high rates. The other two forms are treated differently. Primary cutaneous ALCL confined to one spot is usually treated with radiation or surgical removal, which clears it in about 95 out of 100 people. When skin lesions are widespread or keep returning, a medicine that treats the whole body, such as brentuximab vedotin, is used. Breast implant-associated ALCL is treated by removing the implant together with the entire surrounding scar capsule. When the lymphoma is confined to the capsule with no mass or spread to lymph nodes, many people need no chemotherapy; more extensive disease may also need chemotherapy or radiation.

What to Expect

The outlook depends heavily on which form a person has. Primary cutaneous ALCL usually follows a slow course with excellent long-term outcomes, although new skin lesions can appear over time and need treatment. Breast implant-associated ALCL that is still confined around the implant is usually treated successfully with surgery. ALK-positive systemic ALCL usually responds well to first treatment, and long-term survival in children and teenagers is high. ALK-negative ALCL is more likely to return, and its outlook also varies with genetic features of the lymphoma that specialists can test for. Treatment for systemic ALCL is given in cycles, with regular blood tests to check blood counts. Tiredness and a higher risk of infection are common during chemotherapy, because it lowers the white blood cells that fight infection. Nerve symptoms from brentuximab often improve over the months after treatment ends, though in some people they linger. After treatment, follow-up visits, and sometimes scans, check for relapse and for long-term effects of treatment. Visits usually become less frequent the longer the lymphoma stays in remission. Relapses can occasionally appear after a long remission, which is one reason ongoing follow-up with a team that knows your treatment history matters.

When to Seek Help

See a clinician if you have swollen lymph nodes that do not go away, soaking night sweats or unexplained weight loss, or a skin bump or nodule that keeps growing or does not heal. If you have breast implants, persistent swelling, a lump or pain near an implant should be checked, even many years after surgery. During chemotherapy, a temperature of 100.5°F (38°C) or higher, chills or other signs of infection can mean a serious infection while your white blood cell count is low. Call your care team right away, using the fever instructions they gave you, and check with them before taking fever-reducing medicine, which can hide the problem. Report new or worsening numbness, tingling or weakness in the hands or feet promptly so treatment can be adjusted. After treatment, tell your team about any return of the symptoms that first led to your diagnosis.

Questions to Ask Your Doctor

  1. 1.Which form of ALCL do I have, and is it ALK-positive or ALK-negative?
  2. 2.What did the staging tests show, and how does that shape my treatment plan and outlook?
  3. 3.What is the goal of this treatment, and would a stem cell transplant or a clinical trial make sense for me?
  4. 4.How will we watch for nerve damage, infection and other side effects, and when should I call you?
  5. 5.What will follow-up look like after treatment, and which changes should I report between visits?

Last reviewed • Oct 2026

Educational content, not medical advice.